Ajeet Gajra
YOU?
Author Swipe
View article: Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling
Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling Open
View article: US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization
US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization Open
This retrospective chart review analysis provides evidence for a beneficial impact of eculizumab treatment on the incidence of MG exacerbations and crises and associated healthcare resource utilization in clinical practice, and on rescue t…
View article: United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use
United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use Open
View article: United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use
United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use Open
Background/objectives The phase 3 REGAIN study and its open-label extension demonstrated the efficacy of the complement C5 inhibitor eculizumab in patients with treatment-refractory, acetylcholine receptor antibody–positive generalized mya…
View article: Simplifying informed consent as a universal precaution
Simplifying informed consent as a universal precaution Open
View article: Oncologist Perceptions of Racial Disparity, Racial Anxiety, and Unconscious Bias in Clinical Interactions, Treatment, and Outcomes
Oncologist Perceptions of Racial Disparity, Racial Anxiety, and Unconscious Bias in Clinical Interactions, Treatment, and Outcomes Open
Background: Cancer spares no demographic or socioeconomic group; it is indeed the great equalizer. But its distribution is not equal; when structural discrimination concentrates poverty and race, zip code surpasses genetic code in predicti…
View article: P515: A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING
P515: A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING Open
Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy of older adults (median age at diagnosis: 68 years); median overall survival (mOS) is low, even with treatment. The VIALE-A study (NCT02993523) changed the st…
View article: Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline <i>BRCA</i>-Mutated Advanced HER2-Negative Breast Cancer
Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline <i>BRCA</i>-Mutated Advanced HER2-Negative Breast Cancer Open
Background Talazoparib is a poly (adenosine diphosphate-ribose) polymerase inhibitor approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative, locally advanced or …
View article: Reducing Avoidable Emergency Visits and Hospitalizations With Patient Risk-Based Prescriptive Analytics: A Quality Improvement Project at an Oncology Care Model Practice
Reducing Avoidable Emergency Visits and Hospitalizations With Patient Risk-Based Prescriptive Analytics: A Quality Improvement Project at an Oncology Care Model Practice Open
PURPOSE: Cancer-related emergency department (ED) visits and hospitalizations that would have been appropriately managed in the outpatient setting are avoidable and detrimental to patients and health systems. This quality improvement (QI) …
View article: Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists
Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists Open
Among patients with advanced/metastatic TRK fusion solid tumors, medical oncologists reported that approximately two-thirds initiated a TRKi during the study period. Treatment with a TRKi was longer in duration compared to non-TRKi treatme…
View article: Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study
Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study Open
Jamile Shammo,1 Ajeet Gajra,2 Yogesh Patel,3 Ioannis Tomazos,3 Jonathan Kish,2 Anita Hill,4 J Rafael Sierra,3 David Araten5 1Rush Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, USA; 2Cardinal Health Inc…
View article: CO99 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Utilization Patterns for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among United States (US) Community Hematologists/Oncologists (CH/OS)
CO99 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Utilization Patterns for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among United States (US) Community Hematologists/Oncologists (CH/OS) Open
View article: HSD44 Community Hematologist/Oncologist (CH/O) Barriers to CAR T Referral and Concerns with Possible in-Office CAR-T Administration
HSD44 Community Hematologist/Oncologist (CH/O) Barriers to CAR T Referral and Concerns with Possible in-Office CAR-T Administration Open
View article: CO5 Completeness of Real-World Data (RWD) in Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in United States (US) Community Oncology/Hematology Practices (CH/OS)
CO5 Completeness of Real-World Data (RWD) in Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in United States (US) Community Oncology/Hematology Practices (CH/OS) Open
View article: PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) Open
Background: ESAs are used in first-line treatment for symptomatic or transfusion-dependent anemia in patients with LR-MDS. Ultimately, the majority of patients with LR-MDS who receive an ESA will experience ESA treatment failure. Aims: Thi…
View article: P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA
P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA Open
Background: Bruton tyrosine kinase inhibitor (BTKi) therapies, approved for relapsed or refractory (R/R) mantle cell lymphoma (MCL), have not been comprehensively evaluated in real world populations. Aims: This study aimed to assess patien…
View article: Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice Open
Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment modality where a patient's own T cells are collected and engineered ex vivo to express a chimeric antigen receptor (CAR). These reprogrammed CAR-T cells, …
View article: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer Open
Among patients with advanced/metastatic TRK fusion cancer, medical oncologists reported testing for NTRK fusions at diagnosis or prior to 1L. Future research should elucidate why fewer than half of oncologists surveyed (46%) would not use …
View article: Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers
Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers Open
Background Older adults (≥65 years) with gastrointestinal (GI) cancers who receive chemotherapy are at increased risk of hospitalization caused by treatment-related toxicity. Geriatric assessment (GA) has been previously shown to predict r…
View article: Heterogeneous Versus Homogeneous Radiation Dose Calculations of Twice-Daily Fractionation in Small Cell Lung Carcinoma
Heterogeneous Versus Homogeneous Radiation Dose Calculations of Twice-Daily Fractionation in Small Cell Lung Carcinoma Open
View article: Impact of social determinants of health on cancer care: a survey of community oncologists
Impact of social determinants of health on cancer care: a survey of community oncologists Open
Objective Cancer survival rates have improved over the past few decades, yet socioeconomic disparities persist. Social determinants of health (SDOH) have consistently been shown to correlate with health outcomes. The objective of this stud…
View article: PMS25 Patient-Reported Outcome Labeling for Rheumatoid Arthritis Drugs Approved in the United States: 2010-2019
PMS25 Patient-Reported Outcome Labeling for Rheumatoid Arthritis Drugs Approved in the United States: 2010-2019 Open
View article: PRS30 COVID-19 RAPID Antigen Test False Positives and False Negatives Reported to the FDA Manufacturer and User Facility Device Experience Database
PRS30 COVID-19 RAPID Antigen Test False Positives and False Negatives Reported to the FDA Manufacturer and User Facility Device Experience Database Open
View article: Expanded Access and Right To Try Requests: The Community Oncologist's Experience
Expanded Access and Right To Try Requests: The Community Oncologist's Experience Open
PURPOSE: For patients with cancer who have exhausted approved treatment options and for whom appropriate clinical trials are not available, access to investigational drugs through the US Food and Drug Administration's Expanded Access (EA) …
View article: Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy
Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy Open
PURPOSE: Hospitalizations during cancer treatment are costly, can impair quality of life, and negatively affect therapy completion. Our objective was to identify risk factors for unplanned hospitalization among older adults receiving chemo…
View article: P09.20 Impact of Antibiotics During Immune Checkpoint Inhibitor (ICI) Therapy for Non-Small Cell Lung Cancer: A Real-World Analysis
P09.20 Impact of Antibiotics During Immune Checkpoint Inhibitor (ICI) Therapy for Non-Small Cell Lung Cancer: A Real-World Analysis Open
View article: Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials
Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials Open
These findings suggest that comparing tumor lesion sizes and categorizing treatment response according to RECIST guidelines may be feasible using real-world data. This study found that physician-recorded assessments were associated with ov…
View article: nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis Open
Introduction Despite improvements in the treatment of advanced non-small cell lung cancer (NSCLC), certain patient populations remain underrepresented in clinical trials. Many patients have benefited from platinum doublets, including nab -…
View article: Physician Treatment of Metastatic Triple-Negative Breast Cancer in the Immuno-Oncology Era: a Discrete Choice Experiment
Physician Treatment of Metastatic Triple-Negative Breast Cancer in the Immuno-Oncology Era: a Discrete Choice Experiment Open
Aim: Guidelines list atezolizumab with nab-paclitaxel (ANP) as the preferred first-line (1L) therapy for metastatic triple-negative breast cancer (mTNBC) with PD-L1 expression ≥1%, but which clinical attributes impact ANP prescribin…
View article: Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs Open